Botto M
Rheumatology Section, Division of Medicine, Imperial College School of Medicine, London, UK.
Exp Clin Immunogenet. 1998;15(4):231-4. doi: 10.1159/000019076.
In humans, homozygous deficiency of the first component of the classical pathway of complement, C1q, is a powerful disease susceptibility factor for the development of systemic lupus erythematosus (SLE). This strong association indicates that a functional activity of C1q protects from the development of SLE. Studies in vitro have shown that C1q can bind apoptotic keratinocytes suggesting that it may have an important role in the clearance of apoptotic cells. C1q-deficient mice, generated by gene targeting, showed an increased mortality and 25% of the mice had histological evidence of glomerulonephritis characterised by multiple apoptotic cell bodies and immune deposits, assessed by immunofluorescence and electron microscopy. These observations are compatible with the hypothesis that C1q deficiency causes autoimmunity by an impaired clearance of apoptotic cells.
在人类中,补体经典途径第一成分C1q的纯合缺陷是系统性红斑狼疮(SLE)发生的一个强大的疾病易感性因素。这种强关联表明C1q的功能活性可预防SLE的发生。体外研究表明,C1q可结合凋亡角质形成细胞,提示其可能在凋亡细胞清除中起重要作用。通过基因靶向产生的C1q缺陷小鼠死亡率增加,25%的小鼠有肾小球肾炎的组织学证据,其特征为多个凋亡细胞体和免疫沉积物,通过免疫荧光和电子显微镜评估。这些观察结果与以下假设一致,即C1q缺陷通过凋亡细胞清除受损导致自身免疫。